Clinical Trial Search

Primary: Area Under the Plasma Concentration-time Curve From Time 0 to Infinity (AUC0-inf) Post-dose Period 1 — 110; 260; 364; 176 pg*hr/mL

Primary: Number of Participants Who Experienced at Least One Adverse Event (AE) — 2; 5; 4; 5 Participants

Primary: Area Under the Plasma Concentration-Time Curve From Time Zero to the Last Sampling Time (AUC 0-t) of Metformin — 3740; 3780; 5500; 5540 nanogram*hour per milliliter…

Primary: Comparison of the Vasoconstriction Potential (Skin Blanching Effect) of the MC2-01 Cream With Active Comparators and Vehicle — 1.66; 3.05; 2.45; 1.92 score on a scale

Primary: Area Under the Curve From Time Zero to Infinity (AUC[0-inf]) of GSK2982772 in IR Formulation: Part A — 6.305 Hours*microgram per milliliter

Primary: White Blood Cell Counts — 5.26; 6.99 x10^3 cells/mL

Primary: Number of Phase I Participants With Dose-Limiting Toxicity Events (Phase I) Maximum Tolerated Dose (MTD) (Phase I) as Measured by the Number of Participants With Dose…

Primary: Percentage of Subjects With Drug-related Adverse Events (AEs) — 0.0; 0.0; 0.0; 0.0 Percentage of subjects

Primary: Response to EDQ Question Number 5, "Rate the Degree to Which You Would Like to Take the Drug Again" — 0; 1.714; 2.143; 2.286 units on a scale

Primary: Safety: Number of Participants With at Least One Adverse Event — 10 Participants — p=<0.05

Primary: Number of Subjects With Treatment-emergent Adverse Events (TEAEs) — 10; 10; 10; 10 Participants

Primary: The Primary Safety Endpoint is the Number and Percentage of Participants Per Dose Group and Randomized Allocation, With at Least One of the Following Adverse Events…

Primary: Percentage of Participants With One or More Solicited Injection-site Adverse Events by Severity — 17.2; 21.9; 29.7; 45.3 Percentage of Participants

Primary: Safety (Evaluation of Adverse Events) — 17; 17 Participants

Primary: Cmax — 9180.9; 5925.9; 15224.3; 3758.3 pg/mL